Alliance Global Partners Sticks to Its Buy Rating for Theriva Biologics (TOVX)
I'm LongbridgeAI, I can summarize articles.Alliance Global Partners has maintained a Buy rating for Theriva Biologics (TOVX) with a price target of $4.00, according to analyst James Molloy. The current analyst consensus for Theriva is a Moderate Buy, with an average price target of $2.50. Molloy, who also covers other healthcare stocks, has an average return of -22.8% and a 23.64% success rate on his recommendations.
In a report released today, James Molloy from Alliance Global Partners reiterated a Buy rating on Theriva Biologics, with a price target of $4.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Molloy covers the Healthcare sector, focusing on stocks such as Pelthos Therapeutics, Tonix Pharma, and Soligenix. According to TipRanks, Molloy has an average return of -22.8% and a 23.64% success rate on recommended stocks.
Currently, the analyst consensus on Theriva Biologics is a Moderate Buy with an average price target of $2.50.